Clinical trials: Methotrexate, completed
Rheumatoid Arthritis
Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy
The primary objective of this study is to evaluate the effects of filgotinib in combination with methotrexate (MTX) versus MTX alone in adults with active rheumatoid arthritis (RA).
- Trial name
- FINCH 3 (NCT02886728)
- Testing
- Filgotinib, MTX
- Where
- 186 sites in United States, Argentina and 29 more
- Volunteers
- 1,252 people
- Sponsor
- Gilead Sciences
Rheumatoid Arthritis
Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (RA)
The purpose of this study is to: 1. determine the American College of Rheumatology (ACR) 20 response rate at Day 85 in subjects with active rheumatoid arthritis(RA) administered MDX 1100 with methotrexate (MTX); and 2.
- Trial name
- MDX1100-04 (NCT01017367)
- Testing
- MDX-1100
- Where
- 18 sites in Romania, Ukraine
- Volunteers
- 70 people
- Sponsor
- Bristol-Myers Squibb
Lupus, Psoriatic Arthritis
A Study to Investigate BMS-986165 and Methotrexate in Healthy Male Patients
The purpose of this study is to investigate effects of BMS-986165 on blood levels of methotrexate given as a single dose in healthy male patients.
- Trial name
- NCT03402087
- Testing
- Methotrexate, Leucovorin, BMS-986165
- Where
- Netherlands
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Arthritis, Rheumatoid
The Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) Protocol
The purpose of the study was to evaluate the ability of a maintenance dosage regimen of infliximab to achieve and sustain at least 40% improvement from baseline in the total joint count in patients with active Rheumatoid…
- Trial name
- NCT00246064
- Testing
- infliximab
- Volunteers
- 210 people
- Sponsor
- Centocor Ortho Biotech Services, L.L.C.
Rheumatoid Arthritis
A Dose-range Study of the Safety and Efficacy of Treatment in Adult Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate
The RESOLVE study is a two-part, randomized, double-blind, multi-center, placebo-controlled study of the safety, dose-range finding confirmation, and efficacy of 4 (Part A) and 12 weeks (Part B) of treatment with AP1189 in adult…
- Trial name
- RESOLVE (NCT05604885)
- Testing
- AP1189, 60 mg, AP1189, 80 mg, AP1189, 100 mg
- Where
- Moldova
- Volunteers
- 125 people
- Sponsor
- SynAct Pharma Aps
Rheumatoid Arthritis
A Study to Evaluate the Pharmacokinetics of ASP1707 and Methotrexate in Patients With Rheumatoid Arthritis
The primary purpose of the study is to evaluate the effect of ASP1707 twice daily on the pharmacokinetics of once weekly oral methotrexate (MTX).
- Trial name
- NCT02867306
- Testing
- ASP1707, methotrexate (MTX)
- Where
- Moldova
- Volunteers
- 10 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Rheumatoid Arthritis
Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid Arthritis
This study was intended to evaluate the safety and efficacy of intravenous (IV) ACZ885 and oral methotrexate (MTX) therapy in patients with early rheumatoid arthritis (RA)
- Trial name
- NCT00487825
- Testing
- Canakinumab (investigational), Methotrexate (MTX)
- Where
- 22 sites in United States, Belgium and 4 more
- Volunteers
- 78 people
- Sponsor
- Novartis
Systemic Lupus Erythematosus
Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)
The purpose of this study is to initially access the safety and effectivity of RC18 combined with standard treatment and Placebo combined with standard therapy in subjects with Moderate to severe SLE.
- Trial name
- NCT04082416
- Testing
- RC18 160 mg plus standard therapy
- Where
- China
- Volunteers
- 335 people
- Sponsor
- RemeGen Co., Ltd.
Rheumatoid Arthritis
Study Conducted in Subjects With Rheumatoid Arthritis Who Have Moderate to Severe Disease Activity Despite Methotrexate Therapy With or Without Other Non Biologic Disease Modifying Antirheumatic Drugs (DMARDs)for at Least 12 Weeks Prior to Screening
To compare the maintenance of efficacy of the combination of etanercept 50 mg once weekly plus methotrexate with or without other disease modifying antirheumatic drugs therapy with that of methotrexate with or without other…
- Trial name
- NCT01578850
- Testing
- Etanercept
- Where
- 62 sites in Brazil, China and 17 more
- Volunteers
- 491 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)
Evaluation of efficacy and safety of tofacitinib (CP-690,550) for the treatment of early rheumatoid arthritis in adult patients with moderate to severe disease who are methotrexate naïve.
- Trial name
- NCT01164579
- Testing
- Tasocitinib plus Methotrexate
- Where
- 40 sites in United States, Argentina and 7 more
- Volunteers
- 109 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease
The purpose of this study was to determine how effective and safe the study drug Olokizumab was in patients with Rheumatoid Arthritis (RA) who had been already receiving, but not fully responding to treatment with methotrexate…
- Trial name
- CREDO 1 (NCT02760368)
- Testing
- Olokizumab
- Where
- 40 sites in Belarus, Bulgaria and 1 more
- Volunteers
- 428 people
- Sponsor
- R-Pharm International, LLC
Systemic Lupus Erythematosus
Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)
The purpose of this study is to initially access the safety and effectivity of RC18 combined with standard treatment and Placebo combined with standard therapy in subjects with Moderate to severe SLE, Besides ,to provide dose…
- Trial name
- NCT02885610
- Testing
- RC18 80 mg plus standard therapy, RC18 160 mg plus standard therapy, RC18 240 mg plus standard therapy
- Where
- China
- Volunteers
- 249 people
- Sponsor
- RemeGen Co., Ltd.
Rheumatoid Arthritis
Study of Safety and Efficacy of BCD-020 Comparing to MabThera in Patients With Rheumatoid Arthritis
The purpose of this study is to prove that efficacy, safety and immunogenicity of BCD-020 is equivalent to MabThera when used in combination with methotrexate for the treatment of patient with rheumatoid arthritis
- Trial name
- BIORA (NCT01759030)
- Testing
- Rituximab
- Where
- 40 sites in Belarus, India and 2 more
- Volunteers
- 181 people
- Sponsor
- Biocad
Rheumatoid Arthritis
Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
The primary objective of this study is to evaluate the effects of filgotinib versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA) as measured by the percentage of participants achieving an American…
- Trial name
- FINCH 1 (NCT02889796)
- Testing
- Filgotinib, Adalimumab, MTX
- Where
- 230 sites in United States, Argentina and 28 more
- Volunteers
- 1,759 people
- Sponsor
- Gilead Sciences
Inflammation
Food Effect, Oral & Intravenous Pharmacokinetics and Absolute Bioavailability of BAY1834845 Including Drug-drug Interaction With Methotrexate
This study is planned to explore the effect of food on the oral pharmacokinetics, the intravenous pharmacokinetics and the absolute bioavailability of BAY1834845.
- Trial name
- NCT03244462
- Testing
- BAY1834845, Methotrexate
- Where
- Netherlands
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Bayer
Rheumatoid Arthritis
Safety and Effectiveness Study of RWJ-445380 Cathepsin-S Inhibitor in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy
The primary objective of the study is to evaluate the safety and tolerability of 100, 200, and 300 mg/day doses of RWJ-445380 for up to 12 weeks in patients with active Rheumatoid Arthritis despite methotrexate therapy.
- Trial name
- NCT00425321
- Testing
- RWJ-445380 100 mg, RWJ-445380 200 mg, RWJ-445380 300 mg
- Where
- 42 sites in United States, Argentina and 5 more
- Volunteers
- 259 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Rheumatoid Arthritis
A Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy
This is a randomized, double-blind, placebo-controlled, Phase 2 study to evaluate the safety and efficacy of CCX354-C in subjects with rheumatoid arthritis partially responsive to methotrexate therapy.
- Trial name
- CARAT-2 (NCT01242917)
- Testing
- CCX-354-C, CCX354-C
- Where
- 41 sites in Belgium, Czechia and 6 more
- Volunteers
- 159 people
- Sponsor
- Amgen
Rheumatoid Arthritis
A Retrospective, Observational Chart Review of Biologics in Monotherapy Versus the Combination Biologic Plus Methotrexate in Patients With Rheumatoid Arthritis
This cross-sectional, non-interventional, retrospective chart review will compare the efficacy and safety of biologic monotherapy and biologic and methotrexate combination therapy in patients with rheumatoid arthritis who have…
- Trial name
- NCT01866150
- Where
- 15 sites in United Kingdom
- Volunteers
- 476 people
- Sponsor
- Hoffmann-La Roche
Arthritis, Rheumatoid
Efficacy and Safety of CDP870 and Methotrexate Compared to Methotrexate Alone in Subjects With Rheumatoid Arthritis
The main purpose of the study was to determine the efficacy of CDP870 in treating RA signs/symptoms in patients who were partial responders to MTX.
- Trial name
- NCT00544154
- Testing
- CDP870
- Volunteers
- 247 people
- Sponsor
- UCB Pharma
Gout
Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout
The overall objective of the study is to assess the efficacy, safety, tolerability, and pharmacokinetics (PK) of the concomitant use of pegloticase with methotrexate (MTX) to enhance the response rate seen with pegloticase alone…
- Trial name
- MIRROR OL (NCT03635957)
- Testing
- Pegloticase, Methotrexate (MTX), Standard Gout Flare Prophylaxis
- Where
- 6 sites in United States
- Volunteers
- 14 people
- Sponsor
- Amgen